Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare
Kim S, Bittar M, Kim H, Neelapu S, Zurita A, Nurieva R, Suarez-Almazor M. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. Journal For ImmunoTherapy Of Cancer 2019, 7: 126. PMID: 31088575, PMCID: PMC6518723, DOI: 10.1186/s40425-019-0597-x.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsNivolumab infusionAdverse eventsIL-17 producing CD4Immune checkpoint inhibitor therapyImmune checkpoint inhibitor treatmentImmune-related adverse eventsPatients treated with nivolumabCD4+ T cellsAmount of IL-17Characterized immune cellsCheckpoint inhibitor treatmentPD-1 inhibitorsCheckpoint inhibitor therapyCrystal arthritisSynovial fluidRenal cell carcinomaAutoimmune inflammatory arthritisT helper 17Neutrophil-driven inflammationProphylactic colchicinePD-1Inhibitor therapyConclusionsThis case